Janet Fanaki, Patient and Caregiver Engagement Consultant shared a post by WeTrials on LinkedIn, adding:
“The role that I’ve taken on with WeTrials as a Care Partner Advisor has enabled me to learn so much about different brain tumors and treatments as well as meet leaders in the field.
I hope that this interview with Giselle Sholler will educate those who are caring for a child with a brain tumor, learn more about Beat Childhood Cancer and the important work that this consortium is doing worldwide.
Please share with others.”
Giselle Sholler, Division Chief of Pediatric Hematology/Oncology/BMT at Penn State Health, added to Janet Fanaki‘s post:
“Terrific to participate in the podcast with Janet Fanaki for WeTrials discussing Neuroblastoma and our research! Listen to Part 1 of the Podcast.”
Quoting WeTrials‘s post:
“What is Neuroblastoma?
It’s one of the most common solid tumors in children under six – and one of the toughest to treat.
In this short clip, Dr. Giselle Sholler, Chair of the Beat Childhood Cancer Research Consortium, explains how neuroblastoma forms, why it can spread so quickly, and how newer therapies like DFMO are changing the story for many families.
Every breakthrough begins with a clinical trial – and understanding is the first step toward hope.
Watch the full conversation with Dr. Sholler and Janet Fanaki on the WeTrials Podcast to learn more about:
What clinical trials mean for kids with rare cancers
How families and researchers are working together to find answers
Why collaboration is speeding up access to better treatments
Stay tuned for Part 2, where we dive deeper into how pediatric trials are designed, why collaboration matters, and how the Beat Childhood Cancer network is bringing hope worldwide.
Watch the full episode.
Explore simplified clinical trials.”
More posts featuring WeTrials on OncoDaily.